The sale of Sanofi's controlling stake in consumer health business Opella is expected to close in the second quarter at the ...

The pharmaceutical company forecasts business earnings per share growth at a low double-digit percentage and plans to launch ...

Sanofi said it will repurchase €5 billion ($5.2 billion) of stock and grow profits faster this year as the drugmaker pivots ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Analyst Graham Parry of Bank of America Securities reiterated a Buy rating on Sanofi (SNYNF – Research Report), boosting the price target to ...

Eric Le Berrigaud, an analyst from Stifel Nicolaus, maintained the Buy rating on Sanofi (SNYNF – Research Report). The associated price target ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...

Learn more about whether Sanofi or Zoetis Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.

The company projects mid to high single-digit sales growth in 2025 at constant exchange rates, excluding hyperinflation effects, and low double-digit business EPS growth before foreign exchange and ...